In March 2026, Syneron Bio, a firm dedicated to the advancement of intelligent platform-based macrocyclic peptide drug discovery, proudly announced the successful closure of its Series B financing round. This significant funding milestone was co-led by the esteemed international biotechnology investment fund, Decheng Capital, and CDH VGC, with contributions from a diverse array of institutional investors and unwavering support from its current shareholders. Prior to this, in December 2025, Syneron Bio had already achieved notable success by completing both its Series A and Series A+ financing rounds, amassing a total of nearly US$100 million in capital.

The proceeds from this latest financing round are earmarked for the intelligent enhancement of its proprietary macrocyclic peptide discovery platform, Synova™, as well as propelling its innovative drug pipeline towards clinical development stages. Syneron Bio's drug development portfolio spans a wide range of therapeutic areas. The company's founder emphasized that this infusion of capital will significantly bolster the company's financial strength, expedite the progression of its key drug candidates, further refine the Synova™ platform, and ultimately, deliver groundbreaking treatment options to patients across the globe.

Harnessing the power of the Synova™ platform, Syneron Bio has cultivated a robust pipeline of macrocyclic peptide drugs. Its core team comprises seasoned professionals with a wealth of experience in the field. Moreover, the company has demonstrated remarkable achievement by securing multiple rounds of equity financing within just four years of its inception.